Roche and Janus Biotherapeutics, a Wellesley, Massachusetts-based biopharmaceutical company, have formed a collaboration with Roche for the development of a small- molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are a class of proteins that play a role in the innate immune system in which links TLR activation and signaling with the development of autoimmune disorders. Janus will work exclusively with Roche on TLR research and development. ,/p>

Under the agreement, Janus will receive an upfront cash payment and R&D funding over a collaboration period. Following the achievement of certain predetermined milestones, Roche will have the option to acquire Janus. In the event that the option is exercised, Janus’ shareholders will be eligible to receive an acquisition fee and, potentially, development milestones.

Source: Janus Biotherapeutics